HOME >> BIOLOGY >> NEWS
Inhibition of insulin-like growth factor receptor-1 as promising anticancer therapeutic

Scientists report that an unlikely molecule has emerged as an attractive target for development of therapeutics aimed at a diverse spectrum of tumors, including some malignancies that are resistant to conventional therapies. Two studies published online in Cancer Cell demonstrate that the insulin-like growth factor 1 receptor (IGF-1R) is required for the survival of tumor cells and provide direct evidence that inhibition of IGF-R1 using selective small molecules represents a novel potential anticancer treatment.

Extensive studies have suggested that IGF-1R plays a role in the development of human cancers. IGF-1R is present in a broad range of tumor types including multiple myeloma, lymphoma, leukemia, and breast, lung, prostate, and colon cancers. However, IGF-1R has not been viewed as a likely target for cancer therapeutics because many normal cells also contain the protein. Research scientists from Dana-Farber Cancer Institute in Boston and Novartis Institutes for Biomedical Research Basel demonstrate that IGF-1R inhibition using a variety of methods had potent antitumor effects against many types of cancer cells grown in the laboratory, including cells that are resistant to conventional cancer therapeutics.

Molecular analyses demonstrated that IGF-1R inhibition impacts multiple intracellular signals related to cell proliferation or tumor development and provides possible mechanisms to explain how IGF-1R inhibition can make tumor cells more sensitive to conventional chemotherapy or other anticancer agents. Perhaps most significantly, IGF-1R suppresses tumor growth, prolongs survival, and enhances the antitumor effect of chemotherapy in clinically relevant mouse models of multiple myeloma and other hematological malignancies. The researchers also identify two small molecules that are selective inhibitors of IGF-1R and are active anticancer agents against tumors that contain IGF-1R. These small molecules represent highly attractive potential therapeu
'"/>

Contact: Heidi Hardman
hhardman@cell.com
617-397-2879
Cell Press
26-Feb-2004


Page: 1 2

Related biology news :

1. Inhibition of cathepsin proteases inhibits tumor formation in transgenic mice
2. Inhibition of Borrelia burgdorferi protein may reduce Lyme disease transmission
3. Inhibition Of A Novel Gene Involved In Phosphorylating Starch In TransgenicPotato Tubers Leads To The Repression Of Cold Induced Sweetening
4. Competitive Inhibition May Enhance Safety Of Minimally Processed Fruits And Vegetables
5. Lycopene slows human prostate tumour growth in mice and combined with vitamin E is even better
6. New Arizona State center brings science to policy on issues of water resources and urban growth
7. Researchers identify protein promoting vascular tumor growth
8. IBD (Crohns, Colitis) joins cancer, inflammatory diseases in associated blood vessel growth
9. Growth hormone and IBD: Reduction of intestinal inflammation, promotion of growth
10. Extreme stretch-growth of axons
11. Diabodies act as guided missiles targeted to mammary tumor growth

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/6/2019)... ... 06, 2019 , ... Genomenon® announced the ... includes the ability to search the entirety of the genomic literature by phenotypes ... rare diseases. , Patients, particularly those with rare diseases, don’t always have a ...
(Date:11/5/2019)... ... November 05, 2019 , ... Dr. Lauren Kopp celebrates ... to Seattle, WA, including porcelain veneers , smile makeovers, dental implants, and ... of Washington, Dr. Kopp is passionate about serving her Seattle community with empathy ...
(Date:11/2/2019)... ... November 01, 2019 , ... Stay on top of current hot ... industries. Access to all webinars is free, so be sure to register today to ... Visit http://www.xtalks.com to see our upcoming webinars: , CLINICAL OPERATIONS , November ...
Breaking Biology News(10 mins):
(Date:11/6/2019)... ... November 06, 2019 , ... LeadingBiotech ,?an exclusive event ... its East/West CEO conference to be held January 11-12, 2020 at ... off the week of the J.P. Morgan Healthcare Conference and other biotech industry ...
(Date:11/5/2019)... ... November 05, 2019 , ... ... received CE Mark for its Fusion Bx 2.0 prostate fusion biopsy solution. By ... the Fusion Bx 2.0 will give urologists across Europe the ability to perform ...
(Date:11/2/2019)... ... October 31, 2019 , ... A ... communicating with each other: study managers, principal investigators, supply chain managers, manufacturers, IRT, ... is not informed of the latest data, potentially leading to patient risk. , ...
(Date:11/2/2019)... ... October 31, 2019 , ... ... pharma artificial intelligence pioneer tellic. drug360 brings tellic’s expertise in biomedical language ... allows researchers to quickly uncover relationships between genes, diseases, variants, phenotypes, and other ...
Breaking Biology Technology:
Cached News: